Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. reports news tied to its spatial biology business, including spatial proteomics platforms, multiplex immunofluorescence assays and cancer research collaborations. Company updates have covered the PhenoCycler-Fusion platform, PhenoCode Discovery IO60 panel, single-cell spatial proteomics data resources, immuno-oncology studies and biopharma service offerings for biomarker and translational research.
Akoya news also includes operating and financial results, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. In July 2025, Akoya completed a merger and became a wholly owned subsidiary of Quanterix, making its AKYA public-company news record relevant as historical reference for the former Nasdaq-listed issuer.
Akoya Biosciences (Nasdaq: AKYA) will release its first quarter 2021 financial results after market close on May 18, 2021. Management will discuss these results during a conference call scheduled for 5:00 p.m. ET. Investors can participate by calling (833) 562-0146 domestically or (661) 567-1226 internationally, using Conference ID: 7824008. A live and archived webcast will also be available on the Akoya website.
Akoya is known for its spatial biology solutions, including CODEX® and Phenoptics™ platforms, which allow researchers to explore cell interactions in health and disease.
Akoya Biosciences (Nasdaq: AKYA) has launched its Imaging Innovators Network (I²), inviting researchers to apply innovative uses for the CODEX® system. This initiative aims to push the frontiers of spatial biology through open collaboration and cutting-edge applications. Initially, 10 researchers will be selected to leverage the CODEX system's capabilities, which can analyze over 40 biomarkers in tissue, enhancing disease research. Applications are open until July 9, 2021.
On May 3, 2021, Akoya Biosciences (Nasdaq: AKYA) completed its initial public offering (IPO) by issuing 7,567,000 shares at $20 per share, raising approximately $151 million. This offering included the underwriters' option to purchase an additional 987,000 shares. Akoya specializes in single-cell imaging solutions, utilizing its CODEX® and Phenoptics™ platforms to enhance research in disease progression and treatment response. DLA Piper facilitated this transaction, leveraging its expertise in capital markets and life sciences.
Akoya Biosciences, Inc. (Nasdaq: AKYA) successfully closed its initial public offering (IPO) of 7,567,000 shares at $20.00 per share, raising approximately $151.3 million in gross proceeds. The offering included the full exercise of underwriters' option to purchase an additional 987,000 shares. Trading began on April 16, 2021, on The Nasdaq Global Select Market under the symbol "AKYA." J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity acted as joint book-running managers. The registration statement for the offering was approved by the SEC on April 15, 2021.
Akoya Biosciences has announced the pricing of its initial public offering (IPO) of 6,580,000 shares at $20.00 each, raising approximately $131.6 million before expenses. The offering includes a 30-day option for underwriters to purchase up to 987,000 additional shares. Trading on the Nasdaq under the ticker symbol 'AKYA' is expected to commence on April 16, 2021, with closure anticipated by April 20, 2021, pending usual conditions. J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity are the joint book-running managers for this offering.